Vyne Therapeutics Inc (VYNE) Stock Price, Quote & News

Company Profile

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET i...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 775 7936

Website: vynetherapeutics.com

Address:

685 Route 202/206 N, Suite 301, Bridgewater, United States

nonamestockz Oct. 4 at 7:46 PM

$VYNE big moves are coming - too late shorties

0 · Reply

highnihilism Oct. 4 at 5:16 PM

$VYNE Vyne Therapeutics volume 11,390,461 | average 1,866,959 × 6.1 | price 0.37 +0.05 (+15.3%) earnings 08-14-25 bmo

0 · Reply

StockMasterHere Oct. 4 at 4:14 PM

$EZGO Thank you, bro. Will be loading the boat. Come join the party Check the website: https://www.ezgotech.com.cn/ O/S only 5,675,172 Revenue: $20.1M ( FY 2024 ) Revenue ( FY 2025 Projected ): $100M $ABP $ITP $VYNE $ASBP https://www.sec.gov/ix?doc=/Archives/edgar/data/0001806904/000121390025004698/ea0227793-20f_ezgotech.htm

0 · Reply

WolfofWallasey Oct. 4 at 8:01 AM

$VYNE Well well well . Loading up at .30 might work out nicely here . It took it’s time at that number which is intriguing Feels like someone was loading at .3 or some other reason it was stalled there for so long . My personal view is it was deliberately held at that level give the price action over several weeks Let’s see what’s ahead .

0 · Reply

beppels Oct. 3 at 8:15 PM

$VYNE $GORV and $VYNE my top overniter for Monday!

0 · Reply

SPYmyQQQ Oct. 3 at 7:29 PM

🎯 Target Hit 🏁 📨 From Sep 18, 2025 💊 $VYNE 💵 Entry: $0.3087 ✅ Exit: $0.3684 💰 P/L: +19.33% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

nonamestockz Oct. 3 at 7:28 PM

$VYNE shorties - we meet at 1,5 Dollar

0 · Reply

nonamestockz Oct. 3 at 7:01 PM

$VYNE last day to cover before

0 · Reply

ikan300 Oct. 3 at 6:29 PM

$VYNE $LPTX $DVLT $ATCH if crappy LPTX can run to 70 cents from 30 cents than VYNE should be able to with 40 plus million dollar war chest and no debt unlike lptx!!!!

0 · Reply

ikan300 Oct. 3 at 6:12 PM

$VYNE $LPTX wake up folks VYNE cash rich , low float, almost a year grace period , high volume no brainer!!!!!!!!

0 · Reply

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

Jul 30, 2025, 8:00 AM EDT - 2 months ago

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Jul 2, 2025, 7:45 AM EDT - 3 months ago

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

May 8, 2025, 8:00 AM EDT - 5 months ago

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

Apr 25, 2025, 11:55 AM EDT - 5 months ago

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

Apr 25, 2025, 8:00 AM EDT - 5 months ago

VYNE Therapeutics Provides Update on VYN202 Program

Mar 20, 2025, 8:00 AM EDT - 7 months ago

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 6, 2025, 8:00 AM EST - 7 months ago

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 20, 2025, 8:00 AM EST - 8 months ago

VYNE Therapeutics to Participate in March Investor Conferences

Feb 19, 2025, 8:00 AM EST - 8 months ago

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

Jan 6, 2025, 7:30 AM EST - 9 months ago

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

Dec 23, 2024, 7:30 AM EST - 10 months ago

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Sep 12, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Aug 14, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 26, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

Jun 13, 2024, 9:02 AM EDT - 1 year ago

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

May 9, 2024, 8:00 AM EDT - 1 year ago

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

May 1, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

Mar 19, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Feb 29, 2024, 8:00 AM EST - 1 year ago

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Feb 21, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 16, 2024, 6:50 AM EST - 1 year ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI IBIO

Jan 10, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Jan 3, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

Nov 16, 2023, 4:03 PM EST - 2 years ago

Menlo Ventures Raises $1.35B for AI Investments

Nov 13, 2023, 7:45 AM EST - 2 years ago

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Nov 1, 2023, 4:15 PM EDT - 2 years ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Oct 30, 2023, 7:20 AM EDT - 2 years ago

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Oct 30, 2023, 7:05 AM EDT - 2 years ago

VYNE Therapeutics Announces Private Placement of $88 Million

Oct 30, 2023, 7:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Sep 6, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

May 18, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Attend BIO International Convention

May 11, 2023, 4:01 PM EDT - 2 years ago

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Apr 19, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

Mar 30, 2023, 7:45 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

Mar 22, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

Mar 9, 2023, 4:01 PM EST - 2 years ago

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

Feb 28, 2023, 4:00 PM EST - 2 years ago

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 22, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Feb 15, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

Feb 10, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Reverse Stock Split

Jan 9, 2023, 4:01 PM EST - 2 years ago

VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

Dec 12, 2022, 8:00 AM EST - 3 years ago

VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event

Dec 7, 2022, 8:00 AM EST - 3 years ago

VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform

Dec 2, 2022, 8:00 AM EST - 3 years ago

VYNE Therapeutics to Participate in Cantor Fitzgerald's Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

nonamestockz Oct. 4 at 7:46 PM

$VYNE big moves are coming - too late shorties

0 · Reply

highnihilism Oct. 4 at 5:16 PM

$VYNE Vyne Therapeutics volume 11,390,461 | average 1,866,959 × 6.1 | price 0.37 +0.05 (+15.3%) earnings 08-14-25 bmo

0 · Reply

StockMasterHere Oct. 4 at 4:14 PM

0 · Reply

WolfofWallasey Oct. 4 at 8:01 AM

0 · Reply

beppels Oct. 3 at 8:15 PM

$VYNE $GORV and $VYNE my top overniter for Monday!

0 · Reply

SPYmyQQQ Oct. 3 at 7:29 PM

🎯 Target Hit 🏁 📨 From Sep 18, 2025 💊 $VYNE 💵 Entry: $0.3087 ✅ Exit: $0.3684 💰 P/L: +19.33% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

nonamestockz Oct. 3 at 7:28 PM

$VYNE shorties - we meet at 1,5 Dollar

0 · Reply

nonamestockz Oct. 3 at 7:01 PM

$VYNE last day to cover before

0 · Reply

ikan300 Oct. 3 at 6:29 PM

$VYNE $LPTX $DVLT $ATCH if crappy LPTX can run to 70 cents from 30 cents than VYNE should be able to with 40 plus million dollar war chest and no debt unlike lptx!!!!

0 · Reply

ikan300 Oct. 3 at 6:12 PM

$VYNE $LPTX wake up folks VYNE cash rich , low float, almost a year grace period , high volume no brainer!!!!!!!!

0 · Reply

skyrockets_Inc Oct. 3 at 5:41 PM

$VYNE And let the game's begin. I'm in for 50k more shares.

1 · Reply

Duskfall Oct. 3 at 5:25 PM

$MYNZ Over $2 soon.. $GLMD $QCLS $INTS $VYNE

0 · Reply

ikan300 Oct. 3 at 5:22 PM

$VYNE $LPTX

0 · Reply

artinB Oct. 3 at 5:13 PM

$VYNE break .40 and we will see.60, get in ad enjoy the ride

0 · Reply

revueltoL Oct. 3 at 5:11 PM

$VYNE logging off from trading for today…see you Monday morning with the pivot that this good David Domzalski guy is about to make here..

0 · Reply

ikan300 Oct. 3 at 5:10 PM

$VYNE $LPTX

0 · Reply

revueltoL Oct. 3 at 5:06 PM

$VYNE after hours runner today leading into Monday pre market? I believe so….

0 · Reply

nonamestockz Oct. 3 at 4:59 PM

$MODD soon rocket like $VYNE

1 · Reply

DARKP00L Oct. 3 at 4:40 PM

$VYNE this stock is drawing major attention! Keep watch for market moves!

0 · Reply

ikan300 Oct. 3 at 4:35 PM

$VYNE $LPTX alot of looser biotech with no cash or business like LPTX are going up and VYNE nothing !!!!!

0 · Reply

ikan300 Oct. 3 at 4:13 PM

$VYNE holding huge cash hopefully they use it to create shareholder value!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

0 · Reply

revueltoL Oct. 3 at 3:31 PM

$VYNE we are already lined up at the gates of the disco still stuck behind the bouncers…we’ve got to get past them and into the hall…that’s where the real party begins 😀

0 · Reply

Market Cap	8.23M
Revenue (ttm)	500,000.00
Net Income (ttm)	-39.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,966.00%
Debt to Equity Ratio	0.00

Volume	12,263,801
Avg Vol	2,731,322
Day's Range	N/A - N/A
Shares Out	25.47M
Stochastic %K	56%
Beta	1.91
Analysts	Sell
Price Target	$2.00